ora™ is the industry’s first non-invasive endometrial receptivity test for identifying a patient’s optimal window of implantation (WOI).
Our microRNA-based test analyzes close to 300 microRNA (miRNA) biomarkers in the bloodstream that target over 1000 endometrial receptivity-related genes, alongside other physiological conditions for reliable, actionable results.